結冷膠/胺化石墨烯/阿黴素微粒作為肝癌栓塞試劑之可行性評估

在台灣的十大癌症死因中，肝癌的死亡率佔據第二名，動脈化療栓塞法是目前無法切除時的第一線肝癌治療方法。先前研究出以結冷膠為基材，加入接有阿黴素的胺化石墨烯之微粒，欲深入探討此微粒對肝癌細胞的效用。於結冷膠/胺化石墨烯三種由小至大尺寸微粒的體外釋放，胺化石墨烯的累積濃度分別為55.2 μg/ml、21.15 μg/ml和74.94μg/ml，利用計數顆粒與胺化石墨烯濃度拉出標的準曲線來計算胺化石墨烯的釋放濃度，而其釋放的動力學符合零級和Higuchi模式。用三種尺寸微粒體外釋放胺化石墨烯的累積濃度做細胞存活測試，在第二天時三種濃度的胺化石墨烯細胞存活率都有明顯的下降。用三種尺寸微粒體外釋放胺化石墨烯和阿黴素的累積濃度來觀察細胞凋亡蛋白的表現量，根據上述結果，本研究認為此微粒在體外對於肝癌細胞促使細胞凋亡的效能不錯。

In Taiwan, hepatic carcinoma is the second leading cause of cancer death. Transarterial chemoembolization (TACE) is the first-line treatment at present when liver cancer can’t be resection. In our previous study have made the chemoembolization microsphere (GG/Gra-NH2/DOX) composed of gellan gum (GG), graphene-NH2 (Gra-NH2) and anticancer drugs (Doxorubicin, DOX) in our laboratory. In this study, we focus on the investigation the cellular effect of the GG/Gra-NH2/DOX for HepG2 cells. The Gra-NH2 accumulated concentration of three size microspheres delivery in vitro are 55.2 μg/ml, 21.15 μg/ml and 74.94μg/ml. The standard curve was drawn using the counting Gra-NH2 particles and the concentration to calculate the delivery concentration. The pharmacokinetics of Gra-NH2 match zero order and Higuchi models. Cell viability assay had significantly decline with treated three Gra-NH2 concetration for two days. The percentage of cell apoptosis had significantly increasing with treated two Gra-NH2 concetration and three DOX concentration for one days. From these data, the GG/Gra-NH2/DOX microsphere can promote HepG2 cells apoptosis in vitro.